The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses

被引：8

作者：

Chen, Yungchang ^{[1
]}

Sun, Hao ^{[2
]}

Deng, Yanhong ^{[3
]}

Ma, Yutong ^{[4
]}

Huang, He ^{[5
]}

Liu, Yang ^{[6
]}

Zhang, Yaru ^{[4
]}

Zhang, Hongyu ^{[7
]}

Ye, Sheng ^{[8
]}

Mingyan, E. ^{[9
]}

Guo, Hongqiang ^{[10
]}

Wu, Mengmeng ^{[4
]}

Wu, Chunman ^{[4
]}

Pu, Xingxiang ^{[11
,12
]}

Chen, Xinggui ^{[13
]}

Liang, Chaoyong ^{[14
]}

Ou, Qiuxiang ^{[4
]}

Weng, Huawei ^{[5
]}

Wu, Xue ^{[4
]}

Shao, Yang ^{[4
]}

Gu, Anxin ^{[9
]}

Lin, Tongyu ^{[1
,5
]}

机构：

[1] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Med Oncol, 55, Sect 4,South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China

[2] Chongqing Univ Canc Hosp, Dept Gastrointestinal Canc Ctr, Chongqing 400030, Peoples R China

[3] Sun Yat sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou 510655, Peoples R China

[4] Nanjing Geneseeq Technol Inc, Geneseeq Res Inst, Nanjing 210000, Peoples R China

[5] Sun Yat sen Univ, Collaborat Innovat Ctr Canc Med, Dept Med Oncol, State Key Lab Oncol Southern China,Canc Ctr, Guangzhou 510060, Peoples R China

[6] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Dept Pathol, Sichuan Canc Ctr,Sch Med, Chengdu 610041, Peoples R China

[7] Sun Yat sen Univ, Affiliated Hosp 5, Dept Med Oncol, Zhuhai 519000, Peoples R China

[8] Sun Yat sen Univ, Affiliated Hosp 1, Dept Med Oncol, Guangzhou 510080, Peoples R China

[9] Harbin Med Univ Canc Hosp, Dept Radiat Oncol, 150 Haping Rd, Harbin 150040, Heilongjiang, Peoples R China

[10] Zhengzhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China

[11] Cent South Univ, Hunan Canc Hosp, Dept Thorac Med Oncol, 283 Tongzipo Rd, Changsha 410013, Peoples R China

[12] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, 283 Tongzipo Rd, Changsha 410013, Peoples R China

[13] Guangdong Med Univ, Canc Ctr, Dept Med Oncol, Affiliated Hosp, Zhanjiang 524023, Peoples R China

[14] Guangxi Med Univ, Dept Med Oncol, Canc Hosp, Nanning 530021, Peoples R China

来源：

BIOMARKER RESEARCH | 2023年 / 11卷 / 01期

关键词：

BRAF; Colorectal cancer; Next-generation sequencing; Prognosis;

D O I：

10.1186/s40364-022-00443-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naive colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPortal, we demonstrated that patients with Class3 BRAF mutations had the best survival outcomes compared to the other two subgroups. These findings promoted the development of anti-BRAF strategies by distinguishing BRAF mutant subgroups.

引用

页数：6

共 10 条

[1] Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma
Capaldo, Brian J.
Roller, Devin
Axelrod, Mark J.
Koeppel, Alex F.
Petricoin, Emanuel F.
Slingluff, Craig L., Jr.
Weber, Michael J.
Mackey, Aaron J.
Gioeli, Daniel
Bekiranov, Stefan
[J]. PLOS ONE, 2015, 10 (09):
[2] Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
Jones, Jeremy C.
Renfro, Lindsay A.
Al-Shamsi, Humaid O.
Schrock, Alexa B.
Rankin, Andrew
Zhang, Ben Y.
Kasi, Pashtoon M.
Voss, Jesse S.
Leal, Alexis D.
Sun, James
Ross, Jeffrey
Ali, Siraj M.
Hubbard, Joleen M.
Kipp, Benjamin R.
McWilliams, Robert R.
Kopetz, Scott
Wolff, Robert A.
Grothey, Axel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2624 - +
[3] RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer
Matsumoto, Akio
Shimada, Yoshifumi
Nakano, Mae
Oyanagi, Hidehito
Tajima, Yosuke
Nakano, Masato
Kameyama, Hitoshi
Hirose, Yuki
Ichikawa, Hiroshi
Nagahashi, Masayuki
Nogami, Hitoshi
Maruyama, Satoshi
Takii, Yasumasa
Ling, Yiwei
Okuda, Shujiro
Wakai, Toshifumi
[J]. ONCOLOGY REPORTS, 2020, 43 (06) : 1853 - 1862
[4] Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer
Mondaca, Sebastian
Walch, Henry
Nandakumar, Subhiksha
Chatila, Walid K.
Schultz, Nikolaus
Yaeger, Rona
[J]. GASTROENTEROLOGY, 2020, 159 (05) : 1975 - +
[5] BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues
Sahin, Ibrahim Halil
Klostergaard, Jim
[J]. JCO ONCOLOGY PRACTICE, 2021, 17 (12) : 723 - 730
[6] Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization
Schirripa, Marta
Biason, Paola
Lonardi, Sara
Pella, Nicoletta
Pino, Maria Simona
Urbano, Federica
Antoniotti, Carlotta
Cremolini, Chiara
Corallo, Salvatore
Pietrantonio, Filippo
Gelsomino, Fabio
Cascinu, Stefano
Orlandi, Armando
Munari, Giada
Malapelle, Umberto
Saggio, Serena
Fontanini, Gabriella
Rugge, Massimo
Mescoli, Claudia
Lazzi, Stefano
Bonetti, Luca Reggiani
Lanza, Giovanni
Dei Tos, Angelo P.
De Maglio, Giovanna
Martini, Maurizio
Bergamo, Francesca
Zagonel, Vittorina
Loupakis, Fotios
Fassan, Matteo
[J]. CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3954 - 3961
[7] Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer
Yaeger, Rona
Kotani, Daisuke
Mondaca, Sebastian
Parikh, Aparna R.
Bando, Hideaki
Van Seventer, Emily E.
Taniguchi, Hiroya
Zhao, HuiYong
Thant, Claire N.
de Stanchina, Elisa
Rosen, Neal
Corcoran, Ryan B.
Yoshino, Takayuki
Yao, Zhan
Ebi, Hiromichi
[J]. CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7089 - 7097
[8] Targeting Alterations in the RAF-MEK Pathway
Yaeger, Rona
Corcoran, Ryan B.
[J]. CANCER DISCOVERY, 2019, 9 (03) : 329 - 341
[9] Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Yaeger, Rona
Chatila, Walid K.
Lipsyc, Marla D.
Hechtman, Jaclyn F.
Cercek, Andrea
Sanchez-Vega, Francisco
Jayakumaran, Gowtham
Middha, Sumit
Zehir, Ahmet
Donoghue, Mark T. A.
You, Daoqi
Viale, Agnes
Kemeny, Nancy
Segal, Neil H.
Stadler, Zsofia K.
Varghese, Anna M.
Kundra, Ritika
Gao, Jianjiong
Syed, Aijazuddin
Hyman, David M.
Vakiani, Efsevia
Rosen, Neal
Taylor, Barry S.
Ladanyi, Marc
Berger, Michael F.
Solit, David B.
Shia, Jinru
Saltz, Leonard
Schultz, Nikolaus
[J]. CANCER CELL, 2018, 33 (01) : 125 - +
[10] Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Zhan
Yaeger, Rona
Rodrik-Outmezguine, Vanessa S.
Tao, Anthony
Torres, Neilawattie M.
Chang, Matthew T.
Drosten, Matthias
Zhao, Huiyong
Cecchi, Fabiola
Hembrough, Todd
Michels, Judith
Baumert, Herve
Miles, Linde
Campbell, Naomi M.
de Stanchina, Elisa
Solit, David B.
Barbacid, Mariano
Taylor, Barry S.
Rosen, Neal
[J]. NATURE, 2017, 548 (7666) : 234 - +

← 1 →